Open Access Short Communication Article ID: GJIDCR-6-127

    Hydroxychloroquine as Oral Antidiabetic Agent During Coronavirus Pandemic

    Anirban Majumder*

    The coronavirus disease 2019 (COVID-19) is spreading rapidly. Hydroxychloroquine (HCQ), an old drug for treatment of malaria and autoimmune disease with acceptable safety, has shown promising but yet unproven effect against COVID-19 infection. HCQ is an approved agent by the Drug Controller General of India (DCGI) for the therapy of Type 2 Diabetes. In view of the fact that people with diabetes face higher chance of experiencing serious complications from COVID-19, HCQ may have preferential position as an antidiabetic agent during this crisis period.


    Published on: May 7, 2020 Pages: 6-8

    Full Text PDF Full Text HTML DOI: 10.17352/2455-5363.000027
    Get Citation Base Search Scilit OAI-PMH ResearchGate GrowKudos CrossMark

    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on GJIDCR